Contraception in women with benign breast disease and benign uterine and ovarian conditions

Benign breast diseases (BBDs) deserve attention because of their high prevalence, their impact on women's quality of life (QoL) and, only for some histologic types, their cancerous potential. Fibrocystic breast disease (FBD), recently called "fibrocystic changes," is the most frequent BBD, diagnosed in 50% of clinically and 90% of histopathologically examined women [1].